Phase 3 Trial for Oncolytic Viral Therapy Pexa-Vec in Advanced Liver Cancer Terminated Early
Pexa-Vec, in combination with sorafenib, has failed an interim futility analysis, leading to the early termination of the trial.
General Oncology
FEATURED CONTENT
-
-
Recent Advances Offer Paths Forward for Developing Predictive Biomarkers in Cancer Immunotherapy
Recent advances in predictive biomarker development clarify how best to determine PD-L1 expression in tumor cells. -
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either. -
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems. -
ACP Releases Policy Statement on DOI, COI Management for Clinical Guideline Development
The American College of Physicians endorses the necessity of a comprehensive process for disclosure of potential conflicts of interest to ensure the integrity of clinical guidelines and guidance statements.
GENERAL ONCOLOGY CANCERS NEWS
FDA’s Role in Enforcing Postmarketing Requirements: It’s Complicated
FDA: Nitrosamine Impurity Identified in Commonly Used Acid Suppressant
Malnutrition Common in Older Brazilians Hospitalized for Cancer
Multidisciplinary Approach Maintains, Restores Fertility in Female Patients With Cancer
Cancer Risk From Recalled ARBs “Likely Much Lower” Than Initially Estimated, Says FDA
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
